2022 MEDIPAL Medium-Term Vision
The MEDIPAL Group is implementing initiatives in line with its medium-term vision, “2022 MEDIPAL Medium-Term Vision: Change the Oroshi Future – Innovation for the Future,” a vision aimed at a new Oroshi business model that benefits society with distribution in the fields of pharmaceuticals, health, and beauty, to prepare for changes in the social environment. The MEDIPAL Group has been carrying out further innovation in its existing businesses while shifting its new businesses from the “creation” to the “expansion” stage. At the same time, the MEDIPAL Group is building new frameworks that benefit customers and society through partnerships with companies in various fields, and by doing so, aims to further expand its earnings foundation and achieve sustainable growth.
Basic Policy


We will expand our earnings foundation and achieve sustainable growth
by building new frameworks that benefit customers and society.
Image of Overall Growth


Management Targets
Results for the Fiscal Year Ended March 2020 |
Results for the Fiscal Year Ended March 2021 |
Targets for the Fiscal Year Ending March 2022*2 |
|
---|---|---|---|
Ordinary profit | ¥68.0 billion |
¥52.9 billion |
¥72.0 billion |
Gross profit from new businesses*1 | ¥5.5 billion |
¥6.4 billion |
¥10.0 billion |
Payout ratio | 23.3% |
36.9% |
Stable dividends with target of 30% |
Planned investment in growth | Approx. ¥100.0 billion over three years |
---|
- *1 Gross profit from new businesses that use the MEDIPAL Group’s nationwide infrastructure and human resources. Includes profit from the sale of related products.
- *2 These are the target figures at the time the medium-term vision was announced (May 15, 2019).
Key Strategies by Business
Business | Key Strategies |
---|---|
Prescription Pharmaceutical Wholesale Business |
|
Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business |
|
Animal Health Products Wholesale Business |
|
Food Processing Raw Materials Wholesale Business |
|